Current News

Contact | Print version | PDF version | Send article | RSS-Feed

NascaCell IP GmbH merged with NascaCell Technologies AG

08 May 2006 - The merger between the biotechnology companies NascaCell IP GmbH and NascaCell Technologies AG has been registered under NascaCell Technologies AG with the Munich courts (Handelsregister). Dr. Ernst Böhnlein as CEO and Dr. Michael Blind as CSO are the newly appointed management team. Prior to his appointment, Dr. Böhnlein held managerial positions in the pharmaceutical and biotechnology industries since 1989. In April 2004, he took the position of CEO of Selecore GmbH, a biotechnology company specialised in developing MicrobodyTM therapeutics.
 
Recently, NascaCell has acquired the immaterial assets of Selecore GmbH. Dr. Michael Blind is an expert in the aptamer technology and a co-founder of NascaCell. Most recently, he was CEO of NascaCell IP GmbH.
 
"The aptamer and MicrobodyTM technologies are highly complementary and form the basis to expand our business model", said Dr. Böhnlein, the newly appointed NascaCell CEO. "Based on the aptamer technology, NascaCell IP GmbH has established a service business for various industries. The integration of the MicrobodyTM platform offers NascaCell Technologies AG the opportunity to expand the service offering and to advance product development projects. This is a very attractive and interesting task and I look forward to a successful collaboration with the NascaCell team."